Previous 10 | Next 10 |
home / stock / azncf / azncf news
Sangamo Closes Gene Collaboration with Biogen Sangamo Therapeutics ( SGMO ) reported that it has finalized its sale of stock to Biogen ( BIIB ), leading to the formal initiation of its global licensing collaboration with latter. The collaboration pertains to gene regulation therapies in ...
New York City, NY:March 25, 2020 – Published via (Wired Release) – Recent Research and Future Market Potential of Cystic Fibrosis (CF) Therapeutics Market in Global Industry: 2020 Research and New Innovations in Pharmaceuticals and Healthcare Sector. The prime objective of the re...
Amarin Looks Promising Ahead of Full Year Results, Receives Upgrade Amarin ( AMRN ) received a boost when Citigroup upgraded its stock to Buy. The target price for the stock has been set at $24 a share, showing considerable upside from the current market price, but still below its recent h...
Esperion Therapeutics Anticipates Positive News For Two Of Its Drug Candidates Esperion Therapeutics ( ESPR ) is on the verge of a major catalyst as the company awaits the FDA decision for bempedoic acid as a treatment for increased LDL cholesterol. The agency is scheduled to deliver its...
Veeva ( VEEV ) has been a leader of cloud-based compliance and software solutions for the growing life sciences industry. The business is comprised of two segments: Veeva Commercial Cloud and Veeva Vault. Commercial Cloud is Veeva's flagship product and provides features to customers, inc...
AstraZeneca PLC (AZN) Q4 2019 Earnings Conference Call February 14, 2020 7:00 AM ET Company Participants Pascal Soriot – Chief Executive Officer Dave Fredrickson – Executive Vice President, Oncology Ruud Dobber – Executive Vice President, BioPharmaceutical Bu...
The following slide deck was published by AstraZeneca PLC in conjunction with their 2019 Q4 earnings Read more ...
This article is part of a series that provides an ongoing analysis of the changes made to Kenneth Fisher’s 13F stock portfolio on a quarterly basis. It is based on Fisher Asset Management’s regulatory 13F Form filed on 02/12/2020. Please visit our Tracking Kenneth Fisher's Fis...
As we closed out 2019, I featured the resurgence of some big pharma names ( Bristol-Myers Squibb: 2020 Total Return Play With A 2.8% Dividend Yield ) an d believe they have further room to run in 2020 and beyond. Previously featuring BMY, another name I continue to own is AstraZeneca PLC ...
Quick Take Revolution Medicines ( RVMD ) intends to raise $150 million from the sale of its common stock, according to an amended registration statement. The company is in Phase 1/2 trials for the development of treatments for various types of cancers. RVMD has produced promising early r...
News, Short Squeeze, Breakout and More Instantly...
Inaugural Asia Summit on Global Health successfully explores healthcare landscape HONG KONG, Nov 25, 2021 - (ACN Newswire) - Co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC), the inaugural...
Inaugural Asia Summit on Global Health opens today HONG KONG, Nov 24, 2021 - (ACN Newswire) - Co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC), the inaugural Asia Summit on Global Health (...
A new study with information regarding the “rare but devastating” blood clotting issue affiliated with the Oxford- AstraZeneca (OTCMKTS: AZNCF) Covid-19 vaccine has been released. Nevertheless, according to British scientists, there have been no new cases of blood cl...